GEN Exclusives

More »

GEN News Highlights

Back to Item »

Meda Outlicenses Elidel and Xerese to Valeant for $76M Up Front

Deal will bring Meda another estimated $130 million over next 18 months and royalties of at least $120 million between 2013 and 2015.

Forward this item to a colleague:


(Separate multiple addresses by commas)


(Separate multiple addresses by commas)


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »